Skip to content
April 18, 2024

Equity.Guru

Investment information for the new generation

Search

Charcot-Marie-Tooth disease (CMT)

Acceleron is finding solutions for serious and rare diseases. It has a pipeline of products moving towards commercialisation, including a co-promotion with the $152 billion Bristol-Myers Squibb (BMY.NYSE)…